Uncategorized
Shire’s lifitegrast improves patient-reported symptoms of dry eye in phase 3 trial
The OPUS-3 phase 3 trial of lifitegrast has met its primary endpoint of improving patient-reported symptoms of dry eye disease, according to topline results released by Shire. OPUS-3, a phase 3 efficacy and safety study of lifitegrast vs. placebo, met its primary endpoint of significantly improving patient-reported symptoms from baseline to day 84 (P = .0007), according to a company press release. Patient symptoms significantly improved (P < .0001) at days 14 and 42 as well, thus meetings two “key” secondary endpoints and showing symptom improvement as early as 2 (Read more...)